S63845 |
Katalog-Nr.GC12621
One-Click Copy Product Info
|
S63845 ist ein potenter und selektiver Inhibitor der myeloischen LeukÄmie 1 (MCL1) mit einem Kd-Wert von 0,19 nM fÜr menschliches MCL1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1799633-27-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
S63845 is an effective and selective inhibitor of bone marrow cell leukemia 1 (MCL1), with a Kd value of 0.19nM (for human MCL1) [1]. MCL1 is a pro-survival protein belonging to the BCL-2 family and is overexpressed in many cancers [2]. S63845 can be used for therapeutic research on multiple myeloma, leukemia, and lymphoma cell lines [3].
In vitro, S63845 (0.25, 0.5, and 1.0μM; 24 and 48h) significantly induces apoptosis in two cell lines (HH and HuT-78) in a dose-dependent manner, with decreased cell viability, loss of mitochondrial membrane potential, and activation of caspases [4]. S63845 (0-1280nM; 32 and 48h) in combination with the tyrosine kinase inhibitor imatinib reduces the viability of two cells (K562 and JURL-MK1), and significantly reduces the expression of MCL1, cIAP1, and survivin in K562 cells, while there is a slight upregulation in TCCS cells [5].
In vivo, S63845 (25 and 50mg/kg/day for 5 days; intravenous) can inhibit the generation of red blood cells (RBC) and lymph (LYMPH) in the blood of mice with hematopoietic injury models in the early stage, and restore it in the late stage. During the entire observation period, the platelet (PLT) count in the blood increases [6]. S63845 (25mg/kg/day; twice per week for 3 weeks; intravenous) in combination with regorafenib significantly improves the survival rate of mice in the 143B-luc lung metastasis model [7].
References:
[1] Kotschy A, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016 Oct 27;538(7626):477-482.
[2] Li Z, He S, Look A T. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells[J]. Leukemia, 2019, 33(1): 262-266.
[3] Algarín E M, Díaz-Tejedor A, Mogollón P, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma[J]. Haematologica, 2020, 105(3): e116.
[4] Sumarni U, Zhu J, Sinnberg T, et al. Sensitivity of cutaneous T-cell lymphoma cells to the Mcl-1 inhibitor S63845 correlates with the lack of Bcl-w expression[J]. International Journal of Molecular Sciences, 2022, 23(20): 12471.
[5] Malyukova A, Ujvari D, Yektaei-Karin E, et al. Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells[J]. Cell Death & Disease, 2021, 12(10): 875.
[6] Zhang H, Li F, Yang M, et al. MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis[J]. Pharmaceutics, 2023, 15(4): 1085.
[7] Ji Y, Harris M A, Newton L M, et al. Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo[J]. BMC cancer, 2024, 24(1): 1350.
| Cell experiment [1]: | |
Cell lines | HH and HuT-78 cells |
Preparation Method | Cells were maintained at 37 °C and 5% CO2 in RPMI 1640 growth medium supplemented with fetal calf serum (FCS, 10%), L-glutamine (600μM) and antibiotics. 5 × 104 cells were seeded per well in 24-well plates. Cells were treated with 0.25, 0.5, 1.0µM S63845. After 24 and 48h, apoptotic rates were determined by sub-G1 assay, and rates of cell viability were determined by calcein staining. |
Reaction Conditions | 0.25, 0.5, 1.0μM; 24, 48h |
Applications | S63845 significantly induced apoptosis and reduced cell viability in both types of cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | CB6F1 mice (Hematopoietic Suppression Model) |
Preparation Method | All female mice (6–8 weeks old) were randomly and evenly classified, by weight, into different experimental groups after one week of adaptive rearing under SPF conditions. Mice were classified into three groups: the control group was treated with a vehicle, and the 25mg/kg and 50mg/kg groups were injected with the S63845 solution. S63845 was dissolved in 25mM HCl and 20% 2-hydroxy propyl β-cyclodextrin, which were used as soon as they were ready. The mice were treated with a dose of vehicle or S63845 (the 25mg/kg and 50mg/kg groups) via tail vein injection. This was administered once a day for 5 consecutive days from day 0 (the first day of administration) to day 4. The mice were sacrificed on day 7 or day 22. Peripheral blood (PB) was collected from the tail veins of living mice and analyzed using an automated hematology analyzer. |
Dosage form | 25 and 50mg/kg/day for 5 days; i.v. |
Applications | S63845 initially inhibited the production of red blood cells (RBC) and lymphocytes (LYMPH) in the blood of mice, but restored it in the later stage. During the entire observation period, an increase in platelet (PLT) count was observed. |
References: | |
| Cas No. | 1799633-27-4 | SDF | |
| Chemical Name | (S)-2-(((S)-5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(5-fluorofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methoxy)phenyl)propanoic acid | ||
| Canonical SMILES | OC([C@@H](OC1=NC=NC2=C1[C@]([C@]3=C(C)C(Cl)=C(C=C3)OCCN4CCN(C)CC4)=C(C5=CC=C(F)O5)S2)CC6=CC=CC=C6OCC7=CC=NN7CC(F)(F)F)=O | ||
| Formula | C39H37ClF4N6O6S | M.Wt | 829.26 |
| Löslichkeit | ≥ 41.45mg/mL in DMSO, ≥ 20mg/mL in MeOH | Storage | 4°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2059 mL | 6.0295 mL | 12.0589 mL |
| 5 mM | 241.2 μL | 1.2059 mL | 2.4118 mL |
| 10 mM | 120.6 μL | 602.9 μL | 1.2059 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)